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The larval plerocercoids of Spirometra erina-
ceieuropaei are known to cause “sparganosis” in 
various tissues in the human (Kudesia et al., 1998). 
When the plerocercoids are taken orally in many 
mammals including humans or rodents, the head 
portion of the larva migrated into the peritoneal 
cavity from the intestines.  These plerocercoids 
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Previous studies have shown that excretory/secretory (ES) products from plerocercoids 
of Spirometra erinaceieuropaei have immunosuppressive activities.  We report here that 
a 130 kDa glycoprotein (ES130) purified from ES products as a suppressive factor of 
nitric oxide synthesis in LPS-stimulated RAW 264.7 cells inhibited the gene expression 
of 3 chemokines, regulated on activation normal T cell expressed and secreted (CCL5/
RANTES), macrophage inflammatory protein 2 (CXCL2/MIP-2), interferon-inducible 
protein 10 kDa (CXCL10/IP-10) in RAW 264.7 cells and mouse peritoneal macrophages 
stimulated with LPS for 3 h.  These chemokines are important factors for recruitment of 
inflammatory leukocytes.  RANTES acts on monocytes, basophils, lymphocytes, natural 
killer cells and eosinophils.  MIP-2 is a potent chemoattactant for neutrophils, while IP-
10 binds to Th1 cells.  Nearly 80% of MIP-2 gene expression and 50% of IP-10 gene ex-
pression in peritoneal macrophages stimulated with LPS for 8 h was suppressed as well 
as these chemokine production by the preincubation with 100 ng/mL of ES130 or 5000 
ng/mL crude ES products for 24 h.  On the other hand the mRNA expression of RANT-
ES in macrophages stimulated with LPS for 8 h or 24 h was not inhibited by ES130 or 
crude ES products, while the RANTES chemokine levels in the incubation medium were 
significantly suppressed.  These results suggest that ES130 may attenuate inflammation 
around the plerocercoids by inhibiting these chemokine production.
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Spirometra erinaceieuropaei
may have various bacteria on their surface and 
they bring these bacteria into the peritoneal cav-
ity which, in turn, activates the peritoneal mac-
rophages by the bacterial lipopolysaccharide (LPS). 
LPS is a ligand of Toll-like receptor 4, and has 
been known to be a potent activator of the im-
mune system that induces local inflammation and 
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septic shock (Rietschel and Brade, 1992; Guha 
and Mackman, 2001).  It causes multiple effects on 
macrophages, including the secretion of chemok-
ines for recruitment of inflammatory leukocytes 
and the inflammatory mediators such as interleu-
kin-1 (IL-1) and tumor necrosis factor (TNF)-  
(Hsi and Remick, 1995).
 The chemokines are divided into four fami-
lies on the basis of the arrangement of the first 2 
of 4 conserved cysteins (Ben-Baruch et al., 1995; 
Rottman, 1999).  Many of the CXC chemokines 
are potent chemoattactants for neutrophils, but not 
monocytes, while CC chemokines act on mono-
cytes, basophils, lymphocytes, natural killer cells 
and eosinophils (Wang et al., 1998; Rottman, 
1999).  In the mouse, the CXC family includes 
macrophage inflammatory protein 2 (CXCL2/MIP-
2), interferon-inducible protein 10 kDa (CXCL10/
IP-10) and KC (CXCL1/Gro- ).  MIP-2 and KC 
bind to CXCR1 and /or CXCR2 expressed on neu-
trophils, while IP-10 binds to CXCR3 expressed 
on Th1 cells.  The CC family includes JE/mono-
cyte chemoattactant protein (CCL2/MCP-1) and 
regulated on activation normal T cell expressed 
and secreted (CCL5/RANTES).  RANTES is a li-
gand for CCR1/3/5 expressed on monocytes, mac-
rophages, T cells, dendritic cells and eosinophils 
(Wang et al., 1998; Rottman, 1999).
 The experimentally infected plerocercoids 
do not induce the strong inflammatory responses 
around the parasites and can survive for long peri-
ods in the tissues of mice, hence we hypothesized 
that the larval plerocercoids of S. erinaceieuro-
paei secreted an immunosuppressive factor(s). 
We previously showed that the excretory/secretory 
(ES) products from the plerocercoids suppress the 
LPS-induced expressions of chemokines KC and 
JE (Fukumoto et al., 1997), TNF-  (Miura et al., 
2001; Dirgahayu et al., 2002), and IL-1  (Dirgah-
ayu et al., 2004) in murine macrophages. 
 In the present study, we purified an immuno-
suppressive factor (ES130) of a 130 kDa glycopro-
tein from ES products of plerocercoids and exam-
ined the effect on the chemokine gene expression.
 
Materials and Methods
   
 
Preparation of ES products from plerocer-
coids of Spirometra erinaceieuropaei
 
Plerocercoids of Spirometra erinaceieuropaei were 
collected from 2 species of snakes (Elaphe quadri-
virgata and Rhabdophis tigrinus) in the southern 
part of Ehime Prefecture, Japan and stored for over 
6 to 10 months in the subcutaneous tissue of gold-
en hamsters, which were housed and maintained 
according to the guidelines for proper treatment 
of animals at the Research Center for Bioscience 
and Technology, Tottori University, Japan.  ES 
products were obtained as described previously 
(Miura et al., 2001).  To obtain ES products, 25 
plerocercoids aseptically removed from hamsters 
were incubated for 24 h in 25 mL of Dulbecco’s 
modified Eagle’s medium (DMEM: Invitrogen, 
Carlsbad, CA) in a 10 cm dish.  The medium was 
centrifuged at 10,000  g for 30 min at 4°C to 
remove insoluble debris, then dialyzed against 
25 mM Tris-HCl (pH 7.4) and concentrated with 
Amicon Ultra-15 Centrifugal Filter Units (Nihon 
Millipore, Tokyo, Japan), and subsequently steril-
ized with a 0.22 µm filter (Nihon Millipore).  The 
ES products after sterilization are referred to as 
crude ES products hereafter.  The protein con-
centration was measured using a Bio-Rad protein 
assay kit (Bio-Rad, Hercules, CA), and adjusted to 
500 µg/mL for culture or 250 µg/mL for purifica-
tion.
 
 
Purification of an immunosuppressive fac-
tor from ES products
 
The crude ES products were loaded onto a new 
MonoQ HR5/5 anion-exchange column (Amer-
sham Bio Sciences, Piscataway, NJ) equilibrated 
in 25 mM Tris-HCl (pH 7.4), and the column was 
washed with 10 column volumes of same buffer. 
The bound materials were eluted with a step gra-
dient consisting of 10 column volumes each of 25 
mM Tris-HCl (pH 7.4) containing 0.1, 0.2, 0.3, 0.4, 
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0.5 M NaCl.  These samples were determined for 
their inhibitory effect on the nitrite production in 
RAW 264.7 macrophages (RCB00535) that were 
stimulated with LPS (Escherichia coli serotype 
005:B5) (Difco Laboratories, Detroit, MI).  The 
strongest inhibition was obtained in the fraction 
eluted with Tris-HCl containing 0.3 M NaCl.  For 
further purification, the fractions eluted with 0.3 
M NaCl were applied on Ricinus communis ag-
glutinin (RCA120)- and wheat germ agglutinin 
(WGA)-agarose column (Seikagaku, Tokyo) 
sequentially according to the manufacture’s in-
structions.  To measure the protein concentration, 
the purified proteins and bovine serum albumin 
(Sigma Aldrich, St. Louis, MI), as a standard pro-
tein, were applied to 5% to 20% linear gradient 
polyacrylamide gel (SPG-R520L; ATTO, Osaka, 
Japan) for SDS-PAGE.  After that, the polyacryl-
amide gel was stained with SYPRO Ruby gel 
staining (Invitrogen), and the concentration of the 
purified proteins was quantified by densitometry 
(ATTO Densitograph 4.0; ATTO).
 
Preparation and culture of macrophage
 
RAW 264.7 cells were cultured according to 
Dirgahayu et al. (2004).  Male C57/BL6 mice 
(8-week-old) were purchased from Japan SLC 
(Shizuoka, Japan).  These mice were housed and 
maintained at the Research Center for Bioscience 
and Technology, Tottori University.  Peritoneal 
macrophages were harvested with 10 mL of ice-
cold phosphate-buffered saline on the 3rd day af-
ter intraperitoneal injection of 2 mL thioglycolate 
(Sigma-Ardrich).  The macrophages in DMEM 
containing penicillin G (Banyu Pharmaceutical, 
Tokyo), streptomycin (Meiji Seika, Tokyo) and 
10% heat-inactivated fetal bovine serum (FBS; 
Invitrogen,) were plated in 60 mm tissue culture 
dish (Greiner, Bayern, Germany).  Then the cells 
were incubated at 37˚C in an atmosphere of 5% 
CO2 and were left for more than 14 h before each 
experiment. 
 The culture medium was replaced with a 
fresh DMEM including penicillin G, streptomycin 
and 10% FBS, and either with crude ES products 
(0.5–5.0 µg/mL) or purified ES products (10–200 
ng/mL).  The cells were incubated for 24 h, and 
were stimulated with 100 ng/mL LPS.  After 3 h, 
8 h or 24 h of incubation, the cells were collected 
for isolation of RNA, and the supernatant fluids of 
these dishes were collected for the measurement 
of chemokines by enzyme-linked immunosorbent 
assay (ELISA).
 
 
RNA isolation and semi-quantitative reverse 
transcription-PCR
 
Total RNA was prepared using an ISOGEN Kit 
(Nippon Gene, Tokyo) according to the manufac-
ture’s protocol.  Total RNA (1 µg) was reverse-
transcribed into cDNA using M-MLV Reverse 
Transcriptase (Promega, Tokyo) and random 
primers.  The cDNA was subjected to PCR am-
plification with Taq DNA polymerase (Gene Taq) 
(Nippon Gene).  The primers for IL-1  and TNF-
Table 1.  Chemokine primers and cycle number of PCR
          Gene Primer Product size (bp) Cycle
CCL5/RANTES 5'-CCT CAC CAT CAT CCT CAC TGC A-3'  (forward) 334 34
 5'-CAT CCC CAA GCT GGC TAG GAC T-3'  (reverse)
CXCL2/MIP-2 5'-AGT TTG CCT TGA CCC TGA AGC C-3'  (forward) 466 28
 5'-TGG GTG GGA TGT AGC TAG TTC C-3'  (reverse)
CXCL10/IP-10 5'-CCT ATC CTG CCC ACG TGT TGA G-3'  (forward) 431 23
 5'-CGC ACC TCC ACA TAG CTT ACA G-3' (reverse)
-actin 5'-TGG AAT CCT GTG GCA TCC ATG AAA-3' (forward) 349 22
 5'-TAA ACC GCA GCT CAG TAA CAG TCC-3' (reverse)
IP-10, interferon-inducible protein 10 kDa; MIP, macrophage inflammatory protein; RANTES, regulated on activation 
normal T cell expressed and secreted. 
1 2 3 4
130
(kDa)(kDa)
 200
 116
 94.5
 66
 45
 31
 21.5
 14.5
 6.5
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 were used according to Kina et al. (2005), and 
those for cyclooxygenase-2 (COX-2) were based 
on Fukumoto et al. (2006).  The primers that we 
used for RANTES (Heeger et al., 1992), MIP-2 
(Su et al., 1996), IP-10 (Baker et al., 2003) and 
-actin (Alonso et al., 1986) are listed in Table 1. 
The PCR cycles consisted of denaturation at 94°C 
for 30 s, annealing at 60°C for 1 min and exten-
sion at 72°C for 1min.  The number of cycles for 
semi-quantitative reverse transcriptase-PCR (RT-
PCR) of each gene was also listed in Table 1.  The 
PCR products were separated by electrophoresis 
on 1.5 % agarose gels, and stained with ethidium 
bromide and photographed under UV light with a 
digital camera.  For quantification, electrophoretic 
gels were analyzed using the software Image J 
version 1.33 (National Institutes of Health Bethes-
da, MD).  The amount of mRNAs was normalized 
to that of -actin.
 
Fig. 1.  An immunosuppressive factor, ES130, purified with 
ion-exchange chromatography and lectin chromatography 
was analyzed by SDS-PAGE with SYPRO Ruby gel stain-
ing.  Lane 1, molecular marker; lane 2, crude ES products; 
lane 3, the fraction eluted from the MonoQ column with 
Tris-HCl containing 0.3 M NaCl; lane 4, the fraction eluted 
from the RCA120- and WGA-agarose columns sequentially. 
ES, excretory/secretory; RCA, Ricinus communis agglutinin; 
WGA, wheat germ agglutinin.
 
ELISA analysis
 
The culture medium of 4.0  106 macrophages in 
60 mm dishes was harvested after incubation with 
LPS for 8 h or 24 h.  The collected supernatants 
were stored at –80˚C before measurement.  The 
concentrations of RANTES, MIP-2 and IP-10 
were assayed using ELISA kit (R & D Systems, 
Minneapolis, MN), following the manufacturer’s 
protocol.
 Statistical analysis was performed by non-re-
peated measures analysis of variance.  If there was 
significant difference between the positive control 
and treatment groups, Dunnett’s test was subse-
quently performed.  Data were analyzed with sta-
tistical package software SPSS 12.0 for Windows.
 
 
Results
 
 
Purification of an immunosuppressive fac-
tor (ES130)
 
A suppressive effect on NO synthesis in LPS-stim-
ulated RAW 264.7 cells was found in 0.3 M NaCl 
fraction of crude ES products by an anion exchange 
chromatograpy.  Then we purified a glycoprotein of 
130 kDa, which suppressed NO synthesis in RAW 
264.7 cells, using 2 lectin columns, RCA-agarose- 
and WGA-agarose-columns sequencially (Fig. 1). 
 
 
Suppression of chemokine mRNA expres-
sion in RAW 264.7 cells by ES130 
 
Preincubation with 100 ng/mL of ES130 for 24 h 
suppressed the mRNA expression of 3 proinflam-
matory genes, IL-1 , TNF-  and COX-2, and 3 
chemokine genes, MIP-2, RANTES and IP-10 as 
well as 5 µg/mL of crude ES in RAW 264.7 cells 
stimulated with LPS for 3 h (Fig. 2). 
 
 
Suppression of chemokine mRNA expres-
sion in peritoneal macrophages by ES130
 
No appreciable expression of chemokines was 
observed in control macrophages without LPS 
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stimulation.  Mouse peritoneal macrophages were 
either left untreated or preincubated with various 
doses of ES130 or crude ES products for 24 h.  The 
cells were stimulated with 100 ng/mL LPS for 3 
Fig. 2.  ES130 inhibited the mRNA expression of proinflammatory genes including 3 chemokines in LPS-stimulated RAW 
264.7 macrophages.  RAW 264.7 cells were left untreated or incubated with ES130 (100 ng/mL) or crude ES products (5 µg/
mL) for 24 h, then stimulated with LPS (100 ng/mL) for 3 h.  Total RNA was obtained and the mRNA expression of IL-1 , 
TNF- , COX-2, MIP-2, RANTES, IP-10 and -actin was analyzed by semi-quantitative RT-PCR.  The mRNA levels of 
proinflammtory genes were quantified and were normalized to -actin.  Relative mRNA levels of these genes were presented 
as percentages of the LPS-induced control in the absence of ES130 or crude ES products.  ES, excretory/secretory; IL-1, in-
terleukin-1; IP-10, interferon-inducible protein 10 kDa; LPS, lipopolysaccharide; MIP, macrophage inflammatory protein; 
RANTES, regulated on activation normal T cell expressed and secreted; RT, reverse transcriptase.
Fig. 3.  Suppression of LPS-induced chemokine mRNA expression in 
peritoneal macrophages by ES130.  Peritoneal macrophages were left 
untreated or treated with ES130 (10–200 ng/mL) or crude ES (500–5000 
ng/mL) for 24 h, and then stimulated with LPS (100 ng/mL) for 3 h.  To-
tal RNA was obtained from the cells, and the expression of RANTES, 
MIP-2, IP-10 and -actin mRNA was assessed by semi-quantitative RT-
PCR (A).   The mRNA levels of RANTES, MIP-2 and IP-10 were quan-
tified and were normalized to -actin.  The relative mRNA levels of these 
chemokines were presented as percentages of the LPS-induced control 
in the absence of ES130 or crude ES products (B).  The results are repre-
sentative of independent 2 experiments.   ES, excretory/secretory; IP-10, 
interferon-inducible protein 10 kDa; LPS, lipopolysaccharide; MIP, mac-
rophage inflammatory protein; RANTES, regulated on activation normal 
T cell expressed and secreted; RT, reverse transcriptase.
h.  Crude ES products suppressed 3 chemokine 
gene expression in a dose-dependent manner.  Ten 
to 100 ng/mL of ES130 also suppressed RANTES 
and IP-10 in dose-dependent manner, while about 
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Fig. 4.  Suppression of LPS-induced chemokine mRNA expression in murine peritoneal macrophages by ES130.  Peritoneal 
macrophages were left untreated or treated with ES130 (100 or 200 ng/mL) or crude ES (5000 ng/mL) for 24 h, and then stim-
ulated with LPS (100 ng/mL) for 8 h or 24 h.  Total RNA was obtained from the cells, and the mRNA expression of RANT-
ES, MIP-2, IP-10 and -actin was assessed by semi-quantitative RT-PCR (A).  The mRNA levels of RANTES, MIP-2 and IP-
10 in macrophages stimulated with LPS for 8 h were quantified and were normalized to -actin.  The relative mRNA levels 
of these chemokines were presented as percentages of the LPS-induced control in the absence of ES130 or crude ES products 
(B).  The results are representative of 2 independent experiments.  ES, excretory/secretory; IP-10, interferon-inducible protein 
10 kDa; LPS, lipopolysaccharide; MIP, macrophage inflammatory protein; RANTES, regulated on activation normal T cell 
expressed and secreted; RT, reverse transcriptase.
half of the MIP-2 gene expression was inhibited by 
10 to 100 ng/mL of ES130 (Fig. 3).  However, 200 
ng/mL of ES130 did not inhibit the gene expression 
of 3 chemokines more than the dose of 100 ng/mL. 
 Nearly 80% of MIP-2 gene expression and 
50% of IP-10 gene expression in peritoneal mac-
rophages stimulated with LPS for 8 h were sup-
pressed by the preincubation with 100 or 200 ng/
mL of ES130 or 5000 ng/mL crude ES products 
for 24 h.  The suppressive effect on the gene ex-
pression of MIP-2 and IP-10 continued in mac-
rophages after stimulation with LPS for 24 h.  On 
the other hand, the mRNA expression of RANT-
ES in macrophages stimulated with LPS for 8 h 
or 24 h was not inhibited by ES130 or crude ES 
products (Fig. 4).
 
 
Suppressive effect of ES130 on chemokine 
production in the medium of macrophages
 
The effects of ES130 and crude ES products on 
3 chemokine leves in the incubation medium of 
peritoneal macrophages stimulated with LPS for 8 
h and 24 h were examined by ELISA. 
 MIP-2 concentrations in the medium of LPS-
stimulated macrophages for 8 h and 24 h were 
deeply suppressed by ES130 or crude ES prod-
ucts (Fig. 5) as well as the suppression of MIP-2 
mRNA levels (Fig. 4).  The IP-10 concentration in 
the medium of macrophages stimulated for 8 h or 
24 h was also suppressed by ES130 or crude ES 
products significantly (Fig. 5).
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Abbreviations:  MMP, matrix metalloproteinase; RFLP, 
restriction fragment length polymorphism; TNF, tumor 
necrosis factor
Functional Polymorphisms in the Promoter Regions of 
Matrix Metalloproteinase-2, -3, -7, -9 and TNF-alpha 
Genes, and the Risk of Colorectal Neoplasm in Japanese
Hideyuki Ohtani, Naoto Maeda and Yoshikazu Murawaki
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School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8504 Japan
Colorectal carcinogenesis involves environmental factors and genetic predispositions.  Re-
cent studies have suggested the associations between colorectal neoplasm and functional 
polymorphism of matrix metalloproteinases (MMPs) and cytokine genes.  In this study, we 
analyzed polymorphisms of MMPs and tumor necrosis factor (TNF)-alpha genes, focusing 
on the susceptibility to colorectal neoplasm and the tumor progression.  The subjects were 
186 patients (95 men and 91 women) who underwent total colonoscopy, and were classified 
into cancer, adenoma and non-neoplasm (control) groups of 47, 72 and 67 patients, respec-
tively.  The polymorphisms at the MMP-2 –1306C/T, MMP-3 –1171 5A/6A, MMP-7 –181A/
G, MMP-9 –1562C/T and TNF-alpha –308G/A loci were analyzed.  Regarding background 
factors, significant differences were found in the age, sex ratio and alcohol-drinking and 
cigarette-smoking histories in the adenoma and cancer groups, compared to those in the 
control group.  On these factors-adjusted logistic regression analysis of polymorphisms 
and disease susceptibility, no significant difference was noted in the frequency of any poly-
morphism in the adenoma and cancer groups, compared to those in the control group. 
The analysis of the involvement of polymorphisms in tumor progression in the adenoma 
and cancer groups revealed that the odds ratio for the MMP-3 5A allele was significantly 
higher in the cancer group (2.74; 95% confidence interval = 1.11–6.74, P = 0.02).  The poly-
morphisms of MMP genes and TNF-alpha genes were not associated with the susceptibil-
ity to colorectal neoplasm, but the involvement of the MMP-3 5A allele in the progression 
of adenoma to cancer was suggested. 
Key words:  colorectal neoplasm; gene analysis; matrix metalloproteinase; polymorphism; tumor 
necrosis factor-alpha   
Recently, the rate of colorectal cancer has been 
increasing rapidly in Japan, and it is now the 
main cause of death from malignant disease, as in 
many other countries (Yoshimi and Sobue, 2004). 
In fact, age-standardized rates are similar to those 
in Caucasian populations of the United States 
(Yiu et al., 2004).  The reason has generally been 
ascribed to the Westernized diet, characterized by 
a high intake of fat and meat, popular after World 
War II (Kono, 2004), whereas the relevance of 
genetic predispositions has not been sufficiently 
analyzed in Japanese.  Colorectal neoplasm is 
known to be a multifactorial disease, with dietary 
factors, lifestyle habits and genetic predispositions 
contributing to its development. 
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 Matrix metalloproteinases (MMPs) are pro-
teolytic enzymes that play key roles not only in 
extracellular matrix degradation but also in all 
stages of cancer initiation, invasion and metasta-
sis (Curran and Murray, 1999; Zhu et al., 2001; 
Behrens et al., 2003).  Furthermore, recent studies 
have suggested that MMPs are involved in tumor 
initiation and development, including the regula-
tion of cell proliferation, apoptosis, angiogenesis, 
loss of cell adhesion and immune responses to 
cancer (Egeblad and Werb, 2002).  In fact, the 
over-expression of MMPs has been demonstrated 
in various cancers (Adachi et al., 1999; Ohashi 
et al., 2000; Aglund et al., 2004; Jordan et al., 
2004).  Polymorphisms of MMPs in the promoter 
region, naturally occurring sequence variations, 
may result in the differential expression of MMPs 
in individuals (Ye, 2000).  To date, the promoters 
of MMP-2, -3, -7 and -9 genes have been reported 
to contain polymorphisms, exhibit allele-specific 
effects on the regulation of MMP gene transcrip-
tion, and have been associated with changes in the 
susceptibility to or development of some cancers 
(Liang et al., 2002; Ghilardi et al., 2002, 2003; 
Matsumura et al., 2005).
 On the other hand, previous studies have 
shown that tumor necrosis factor (TNF)-alpha 
expression may act as a high-risk factor or a poor 
prognostic factor in some cancers (Warzocha et 
al., 1997; El-Omar et al., 2003; Machado et al., 
2003; Sharma et al., 2008).  However, a few previ-
ous reports have suggested that there is no signifi-
cant association between the TNF-alpha –308A/G 
polymorphism allele and colorectal cancer devel-
opment (Park et al., 1998; Landi et al., 2003). 
 To explore the possible association between 
these polymorphisms and the risk of colorectal 
neoplasms, we analyzed promoter genes in MMP-
2, -3, -7 and -9 and TNF-alpha in a Japanese sam-
ple of colorectal neoplasm patients and controls 
who had no finding of colonoscopy.
 
Materials and Methods
 
Subjects
 
A total of 186 Japanese subjects (91 women and 
95 men, with a mean age of 64 ± 13 years) were 
studied between August 2003 and March 2007. 
All subjects had undergone total colonoscopy 
just prior to enrollment.  One hundred nineteen 
patients with histologically confirmed colorectal 
neoplasm (47 cancers and 72 adenomas) and 67 
non-neoplasm subjects (controls) were interviewed 
regarding their medical history, family history of 
colorectal cancer, anamnesis of diabetes, and hab-
its such as alcohol intake and cigarette smoking. 
Before enrollment and blood sampling, written 
informed consent was obtained from all recruited 
subjects.  This study was approved by the Ethics 
Committee of Tottori University Faculty of Medi-
cine.
 
Table 1.  Sequences of PCR primers 
Gene Polymorphism Forward primer and reverse primer (5´–3´) Tm Restriction
   (˚C) enzyme
MMP-2 –1306 C/T CTT CCT AGG CTG GTC CTT ACT GA 60 Xsp I
   CTG AGA CCT GAA GAG CTA AAG AGC T
MMP-3 –1171 5A/6A CTT CCT GGA ATT CAC ATC ACT GCC ACC ACT 65 Tth111 I
   GGT TCT CCA TTC CTT TGA TGG GGG GAA AGA
MMP-7 –181 A/G TGG TAC CAT AAT GTC CTG AAT GAT ACC TAT G 65 EcoR I
   TCG TTA TTG GCA GGA AGC ACA CAA TGA ATT
MMP-9 –1562 C/T GCC TGG CAC ATA GTA GGC CC 60 Sph I
   CTT CCT AGC CAG CCG GCA TC 
TNF-alpha –308 G/A GAG GCA ATA GGT TTT GAG GGC CAT 55 Nco I
   GGG ACA CAC AAG CAT CAA G
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DNA extraction
 
Genomic DNA samples were extracted from pe-
ripheral white blood cells using a DNA extracting 
kit (DnaQuickII: Dainipponseiyaku, Osaka, Ja-
pan) according to the manufacturer’s instructions.
 
 
Determination of genotypes
 
Using the extracted DNA as a template, the pro-
moter region of each MMP was amplified by PCR 
using commercially available kits (HotStarTaq: 
QIAGEN, GmbH, Germany), following the manu-
facturer’s instructions.  The sequences of primers 
are summarized in Table 1.  The methods used 
to type the MMP-2 –1306 C/T, MMP-3 –1171 
5A/6A, MMP-7 –181A/G, MMP-9 –1562 C/T and 
TNF-alpha –308 G/A polymorphisms have been 
described previously (Jormsjö et al., 2001; Vasku 
et al., 2004; Zhang et al., 2004; Perri et al., 2005; 
Tuet al., 2007).  Briefly, reactions were carried out 
under the following conditions:  5 min at 95˚C, 
and then amplification for 35 cycles consisting of 
30 s at 95˚C, 30 s at an appropriate temperature 
and 30 s at 72˚C.  A final extension step at 72˚C 
for 5 to 10 min was added to terminate the am-
plification.  Subsequently, the PCR products were 
digested with appropriate restriction enzymes that 
cleave from 1 to 2 fragments.  The digests were 
then electrophoresed on a 1 to 2% agarose gel us-
ing TBE buffer (45 mM Tris-borate, pH 8.3, and 
2 mM EDTA) to confirm cleavage using molecu-
lar size marker IV (Nippon Gene, Tokyo, Japan). 
Gels were stained with ethidium bromide and 
visualized under UV light. As examples for gel 
documentation, the results of MMPs genotyping 
were shown in Fig. 1. 
Fig. 1.  Genotyping of MMP-2 C/T, MMP-3 5A/6A, MMP-7 A/G and MMP-9 C/T by PCR-restriction fragment 
length polymorphism.  
A: MMP-2 C/T.  The PCR products were digested with XspI restriction enzyme and subjected to electrophoresis on a 2.5% 
agarose gel.  M, molecular marker; 1 and 2, C/T genotype; 3, 4 and 5, C/C genotype.
B: MMP-3 5A/6A.  The PCR products were digested with Tth111I restriction enzyme and subjected to electrophoresis 
on a 2.5% agarose gel.  M, molecular marker; 1, 3 and 4, 6A/6A genotype; 2, 5A/5A genotype; 5, 5A/6A genotype.
C: MMP-7 A/G.  The PCR products were digested with EcoRI restriction enzyme and subjected to electrophoresis on a 
2.5% agarose gel.  M, molecular marker; 1, 2 and 4, A/A genotype; 3 and 5, A/G genotype.
D: MMP-9 C/T.  The PCR products were digested with Sph I restriction enzyme and subjected to electrophoresis on a 
2.5% agarose gel.  M, molecular marker; 1 and 4, C/C genotype; 2 and 3, C/T genotype; 5, C/T genotype.
MMP-2 (–1306 C/T):  Xsp I
MMP-7 (–181 A/G):  ExoR I
MMP-3 (–1171 5A/6A):  Tth111 I
MMP-9 (–1562 C/T):  Sph I
M 1 2 3 4 5
M 1 2 3 4 5
M 1 2 3 4 5
M 1 2 3 4 5
C/T C/C
A/A A/G
6A/6A 5A/5G 5A/6A
C/C C/T T/T
— 193
— 162
194 —
118 —
— 150
— 120
— 435
— 247
— 188
603 —
310 —
234 —
194 —
— 129
— 97
194 —
118 —
(bp) (bp)
A
C
B
D
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Statistical analysis
 
The significance of differences in means or propor-
tions was measured using analysis of variance or 
the chi-square test.  Comparison of the genotypes of 
MMP-2, -3, -7 and -9 and TNF-alpha and the allelo-
type distribution in the study groups was performed 
by means of a 2-sided contingency table using the 
chi-square test.   Relationships between the geno-
types and clinicopathological characteristics of the 
patients were evaluated by Fisher’s exact test.  To 
evaluate the increased risk of colorectal neoplasm 
associated with the presence of polymorphic al-
leles, odds ratios and 95% confidence intervals were 
computed, adjusted by logistic regression for several 
covariates potentially associated with the colorectal 
neoplastic risk such as age, sex, family history of 
colorectal cancer, alcohol intake, smoking status 
and diabetes mellitus.  All statistical analyses were 
performed using the software package SPSS II for 
Windows (version 11.0 J, SPSS Japan, Tokyo)
 
 
Results
 
 
Characteristics of subjects
 
Subjects who had undergone colonoscopy were 
divided into a control group with no finding and 
patient groups with adenoma or cancer of the 
colon.  The backgrounds of groups are shown 
in Table 2.  The mean age was 67.3 ± 1.7 years 
(range: 27–90) in the colorectal cancer group and 
66.3 ± 1.1 years (range: 36–88) in the adenoma 
group.  Compared to the control group, significant 
differences were noted in the age, sex ratio and 
alcohol-drinking history in the adenoma and can-
cer groups.  No significant difference was noted 
in the cigarette-smoking history between the ad-
enoma and control groups (P = 0.10), but one was 
present between the cancer and control groups (P 
= 0.01).  There were no significant differences in 
the familial medical history of colorectal cancer 
or anamnesis of diabetes, compared to the control 
group.
 On comparison of the adenoma and cancer 
groups, no significant differences were present in 
the age, sex ratio, or alcohol-drinking or cigarette-
smoking history, but the frequency of familial 
medical history of colorectal cancer was signifi-
cantly higher in the cancer group (P = 0.007). 
The frequency of anamnesis of diabetes was 
slightly higher in the cancer group, but the differ-
ence was not significant (P = 0.08). 
 
 
Genotype distributions and the suscepti-
bility for adenoma and cancer
 
The frequencies and odds ratios of polymor-
phisms of the MMP-2, -3, -7 and -9 and TNF-
Table 2.  Characteristics of subjects
 Control [67] Patient with
 Ratio Adenoma [72] Cancer [47] 
  Ratio  P† Ratio P†  P‡
Age (year)  61.3 ± 2.0 66.3 ± 1.1 0.04 67.3 ± 1.7 0.04  NS
Sex    Male/female 25/42 42/30 0.02 28/19 0.03  NS
Family history§     Yes/no  8/59  3/69  NS 10/37  NS 0.008
Smoking status     Smoker/non-smoker 19/48 31/41  NS 26/21 0.006  NS
Alcohol status     Drinker/non-drinker 21/46 36/36 0.03 25/22 0.03  NS
Diabetes     Yes/no  5/62  5/67  NS  9/38  NS  NS
 [  ], number of subjects.  
 Ratio, except age (mean ± SD).
 NS, not significant. 
† Compared with the control subjects.
‡ Compared with patients with adenoma.
§ Patients with family history of colorectal cancer in the 1st degree relatives.
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alpha gene are shown in Table 3.  Regarding the 
distribution of alleles in our study, most patients 
had C/C alleles in MMP-2, 6A/6A in MMP-3, A/
A in MMP-7, C/C in MMP-9 and G/G in TNF-
alpha, and, in reverse, none had G/G alleles in 
MMP-7, nor A/A alleles in TNF-alpha.
 Logistic regression analysis adjusted for age, 
sex ratio, and alcohol-drinking and cigarette-
smoking histories, which were background factors 
with significant differences, was performed in the 
control, adenoma and cancer groups. 
 There were no significant differences of 
these genotypes between controls and adenoma 
patients, and between controls and cancer patients, 
suggesting that colorectal neoplasm susceptibility 
was not found in any polymorphism of the MMP-
2, -3, -7 and -9 or TNF-alpha gene. 
Table 3.  Genotype and allele frequencies of polymorphisms of the MMP-2, -3, -7 and -9 and TNF-
alpha gene in controls and patients
     Genotype  Control [67] Patient with adenoma [72] Patient with cancer [47]
     and allele Number Number   Odds ratio† P Number    Odds ratio†   P
 (%)    (%) (95% CI)  (%) (95% CI)
MMP-2 –1306 C/T
     CC 64 (95) 66 (92) 1  41 (87) 1
     CT 3 ( 5) 6 ( 8)   5 (11)
     TT 0 ( 0) 0 ( 0)   1 ( 2)
     CT + TT 3 ( 5) 6 ( 8) 2.39 0.26 6 (13) 2.98 0.17
      (0.51–11.7)     (0.62–14.29)
     T 0.02  0.04    0.07
MMP-3 –1171 5A/6A
     6A6A 50 (75) 58  (81) 1  31 (66) 1
     6A5A 17 (25) 13 (18)   14 (30)
     5A5A 0 ( 0) 1 ( 1)   2 ( 4)
     6A5A + 5A5A 17 (25) 14 (19) 0.79 0.59 16 (34) 1.56 0.32
      (0.34–1.84)     (0.64–3.81)
     5A 0.13  0.1    0.19 
MMP-7 –181 A/G
     AA 55 (82) 65 (90) 1  45 (96) 1
     AG 12 (18) 7 (10)   2 ( 4)
     GG 0 ( 0) 0 ( 0)   0 ( 0)
     AG + GG 12 (18) 7 (10) 0.61 0.35 2 ( 4) 0.21 0.06
      (0.21–1.75)     (0.40–1.11)
     G 0.09  0.05    0.02
MMP-9 –1562 C/T
     CC 47 (70) 54 (75) 1  30 (64) 1
     CT 19 (28) 17 (24)   16 (34)
     TT 1 ( 2) 1 ( 1)   1 ( 2)
     CT + TT 20 (30) 18 (25) 0.78 0.53 17 (36) 1.41 0.41
      (0.35–1.71)     (0.61–3.28)
     T 0.16  0.19    0.13
TNF-alpha –308 G/A 1
     GG 65 (97) 71 (99) 1  46 (98) 1
     GA 2 ( 3) 1 ( 1)   1 ( 2)
     AA 0 ( 0) 0 ( 0)   0 ( 0)
     GA + AA 2 ( 3) 1 ( 1) 0.62 0.71 1 ( 2) 0.77 0.83
      (0.04–8.02)     (0.06–9.31)
     A 0.01  0.01    0.01
 [  ], number of subjects.
 CI, confidence interval.
† Odds ratio adjusted on age, sex, smoking and alcohol status.
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Table 4.  Genotype and allele frequencies of poly-
morphisms of the MMP-2, -3, -7 and -9 and TNF-
alpha gene in patients with adenoma and cancer
   Genotype    Patient with  P
        and  Adenoma Cancer
      allele [72] [47]
 Number  Number  Odds ratio† 
 (%) (%) (95% CI)
MMP-2 –1306 C/T
     CC 66 (92) 41 (87) 1
     CT + TT 6 ( 8) 6 (13) 1.54 0.49
      (0.43–5.488)
MMP-3 –1171 5A/6A
     6A6A 58  (81) 31 (66) 1
     6A5A + 5A5A 14 (19) 16 (34) 2.74 0.02
      (1.11–6.74)
MMP-7 –181 A/G
    AA 65 (90) 45 (96) 1
     AG + GG 7 (10) 2 ( 4) 0.58 0.52
      (0.11–3.00)
MMP-9 –1562 C/T
     CC 54 (75) 30 (64) 1
     CT + TT 18 (25) 17 (36) 1.43 0.41
      (0.61–3.37)
TNF-alpha –308 G/A
     GG 71 (99) 46 (98) 1
     GA + AA 1 ( 1) 1 ( 2) 0.58 0.58
      (0.13–36.13)
 CI, confidence interval.  
† Odds ratio adjusted on family history and diabetes.
 
Association with tumor progression
 
To investigate the association with tumor progres-
sion from adenoma to cancer, the frequencies and 
odds ratios of polymorphisms of the MMP-2, -3, 
-7 and -9 and TNF-alpha gene in the adenoma and 
cancer groups were calculated (Table 4).  Logistic 
regression analysis adjusted for a familial history 
of colorectal cancer and anamnesis of diabetes 
was performed.  We found that patients with the 
MMP-3 5A allele had significantly higher odds 
ratio (2.74) of cancer (P = 0.02).  However, other 
genotypes showed no significant difference be-
tween the adenoma and cancer groups.
 
 
Discussion
 
It has been reported that MMPs play an important 
role in various cancer metastases and invasion 
including colorectal cancer (Asano et al., 2007), 
but no consistent finding has been obtained with 
regard to the association of any MMP gene poly-
morphism with colorectal cancer progression. 
Similarly, no association between TNF-alpha and 
colorectal cancer has been identified.  We inves-
tigated polymorphisms of the MMP-2, -3, -7 and 
-9 and TNF-alpha gene and the susceptibility 
to colorectal neoplasm.  In addition, consider-
ing that most colorectal cancer cases develop via 
the adenoma-carcinoma sequence (Fearon and 
Vogelstein, 1990), we studied the association of 
tumor progression with each gene polymorphism.  
MMP-2 expression in colorectal cancer tissue has 
been reported to be correlated with the disease 
stage and prognosis, and considered to play an 
important role in colorectal cancer invasion and 
metastasis (Turpeenniemi-Hujanen, 2005).  In the 
MMP-2 gene, C/T polymorphism is present at 
–1306, and the transcription activity is higher in 
the C than in the T allele (Price et al., 2001).  In 
studies reported by Heittaratchi et al. (2007) and 
Elander et al. (2006), –1306 C/T was not associat-
ed with the sensitivity of colorectal cancer, 5-year 
survival rate or tumor characteristics, whereas Xu 
et al. (2004) reported that the risk of colorectal 
cancer development was higher in CC than in CT 
and TT types, showing that no consistent findings 
have been obtained with regard to the association 
of MMP-2 gene polymorphisms with colorectal 
cancer.  In our study, no association of MMP-2 
gene polymorphisms with the susceptibility to col-
orectal neoplasm or tumor progression was noted.
 In colorectal cancer tissues, MMP-3 is 
mainly expressed in stromal cells (Newell et al., 
1994).  In the MMP-3 gene, 5A/6A polymorphism 
is present at –1171, and the transcription activity 
is higher in the 5A than in the 6A allele (Ye et al., 
1996).  Hinoda et al. (2002) reported that the 6A 
allele with low transcription activity indirectly 
contributed to colorectal cancer development, but 
no other study has supported this finding (Biondi 
et al., 2000; Ghilardi et al., 2001; Xu et al., 2006; 
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Hettiaratchi et al., 2007).  The clinicopathologi-
cal significance of the MMP-3 expression in col-
orectal cancer remains unclear.  No association 
with colorectal neoplasm susceptibility was noted 
in the present study, but the frequency of the 5A 
allele with high transcription activity during the 
progression of adenoma to cancer was high in the 
cancer group.  Sternlicht et al. (1999) investegated 
the MMP-3 in the breast cancer, and reported 
that MMP-3 promoted spontaneous premalignant 
changes and malignant conversion in the mam-
mary glands of transgenic mice.  Furthermore, re-
garding breast cancer, Nelson et al. (2008) report-
ed that the overproduction of MMP-3 in mam-
mary gland tissue triggered surrounding cells to 
increasingly produce reactive oxygen species, and 
induced DNA injury and genetic instability, fi-
nally leading to malignant conversion.  Colorectal 
cancer may develop via a similar course. 
 While MMP-7 has a broad substrate speci-
ficity, it also exhibits “sheddase” activity mediat-
ing cell surface protein release, and its influence 
on the growth and progression of colorectal, 
esophageal, stomach, and lung cancers has been 
investigated (Leeman et al., 2003; Zhang et al., 
2005).  A strong correlation of MMP-7 with col-
orectal cancer malignancy has been reported, in 
which the expression frequency of MMP-7 was 
particularly high in cancer tissues, and the MMP-
7 expression level was higher in metastatic le-
sions than in the primary lesion (Yoshimoto et al., 
1993).  In the MMP-7 gene, A/G polymorphism 
is present at –181 of the promoter lesion, and the 
transcription activity is higher in the G than in 
the A allele (Ghilardi et al., 2003).  Ghilardi et 
al. (2003) reported that the MMP-7 –181 G/G 
genotype was involved in colorectal cancer and 
tumor progression in Italians, but we detected no 
association of MMP-7 gene polymorphisms with 
colorectal neoplasm susceptibility or tumor pro-
gression.  One reason may have been the biased 
distribution of MMP-7 polymorphisms.  The fre-
quency of MMP-7 G/G was about 0.5% in healthy 
subjects in a study performed in China (Lu et al., 
2006), but about 20% in another Asian country, 
India (Singh et al., 2008), suggesting regional 
variation.  Actually, none of the subjects analyzed 
showed MMP-7 G/G in our study. 
 Regarding MMP-9, Zucker and Varcrca 
(2004) reported that the MMP-9 level rose in an 
early stage after the progression of adenoma to 
colon cancer, and Roeb et al. (2001) reported that 
MMP-9 transcription activity was 5 times higher 
in colorectal cancer than in the normal mucosa. 
In the MMP-9 gene, T/C polymorphism is present 
at –1562, and the transcription activity is higher 
in the C than in the T allele (Zhang et al., 1999). 
Matsumura et al. (2005) reported a relationship 
between stomach cancer invasion and the MMP-9 
T allele position, and Grieu et al. (2004) reported 
that C homo improved the prognosis of breast 
cancer.  Regarding colorectal cancer, Elander et 
al. (2006) investigated the relationship between 
C/T polymorphism at –1562 and colorectal can-
cer, and found no correlation, as observed in our 
study.
 In the TNF-alpha gene, G/A polymorphism 
is present at –308, and the transcription activity 
is higher in the A than in the G allele (Abraham 
and Kroeger, 1999).  Previous reports, however, 
support that there is no significant association be-
tween the TNF-alpha –308 A/G allele and colorec-
tal cancer susceptibility (Park et al., 1998; Landi et 
al., 2003).  The findings of our study are similar to 
those reports.
 The present study clarified that the suscep-
tibility to colorectal cancer is more strongly af-
fected by age, gender, and cigarette-smoking and 
alcohol-drinking histories in Japanese, as reported 
by Otani et al. (2003), than gene polymorphisms 
studied.  Colorectal cancer is a multifactorial dis-
ease involving environmental factors as well as 
a genetic predisposition, and properly cannot be 
explained by genetic predisposition alone.  How-
ever, detailed clarification of the involvement of a 
genetic predisposition may contribute to the pre-
diction and early discovery of cancer development 
as well as elucidation of the molecular mechanism 
involved in the carcinogenic factors and early 
stage of carcinogenesis. 
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 In conclusion, no association with the sus-
ceptibility to colorectal neoplasm was noted in 
any polymorphism of the MMP-2, -3, -7 and -9 
and TNF-alpha genes, but the involvement of the 
MMP-3 5A allele in tumor progression was sug-
gested.  
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